Approval · Notice of Compliance 796 · 2002
LIN WARFARIN: Notice of Compliance 796
Issued January 2, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 796
- Date
- January 2, 2002
- Company
- Linson Pharma Co.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Anticoagulant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIN WARFARIN | 02152460 | — |
| LIN WARFARIN | 02152479 | — |
| LIN WARFARIN | 02152487 | — |
| LIN WARFARIN | 02152495 | — |
| LIN WARFARIN | 02152509 | — |
| LIN WARFARIN | 02152517 | — |
Medicinal ingredients
- WARFARIN SODIUM 1 MG per TAB
- WARFARIN SODIUM 2 MG per TAB
- WARFARIN SODIUM 2.5 MG per TAB
- WARFARIN SODIUM 4 MG per TAB
- WARFARIN SODIUM 5 MG per TAB
- WARFARIN SODIUM 10 MG per TAB